SCYNEXIS Inc

NASDAQ:SCYXUnited States

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Contact Information

Headquarters

1 Evertrust Plaza, 13Th FloorJERSEY CITY, NJ, United States 07302-6548

Phone

201-884-5485

Fax

919-544-8697

Executives

Non-Executive Independent Chairman of the Board

Guy Macdonald

President, Chief Executive Officer, Director

David Angulo

Chief Financial Officer

Ivor Macleod

General Counsel

Scott Sukenick

Independent Director

Armando Anido